Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
February 26, 2025

Notice Regarding Transition to a Company with Audit and Supervisory Committee Structure

At the Board of Directors' meeting held today, Alfresa Holdings Corporation passed a resolution to transition from a company with audit and supervisory board structure to a company with audit and supervisory committee structure, both as described in the Companies Act of Japan, subject to approval at the 22nd Ordinary General Meeting of Shareholders to be held in June 2025. Details are as follows.

1. Purpose of the Transition

As a corporate group operating in areas related to life and health, the Alfresa Group has established its Principles,* which comprise Our Philosophy, Our Vision, and Our Promises. The Group fulfills its corporate social responsibilities through the implementation of these principles and believes that enhancing corporate governance is fundamental to improving its corporate value.

Although we have endeavored to enhance corporate governance under the current company with audit and supervisory board structure, we recognize that we must build a governance structure that responds more quickly to changes in our operating environment. Transitioning to a company with audit and supervisory committee structure will enable prompt management decision-making through the separation of business supervision and execution and the transfer of authority by delegating substantial decision-making authority on business execution from the Board of Directors to directors. In addition, we will bolster the monitoring functions of the Board of Directors by appointing directors who are Audit and Supervisory Committee members with voting rights at Board of Directors' meetings, thus better enhancing our corporate governance and further improving our corporate value.

* The Alfresa Group's Principles
https://www.alfresa.com/eng/about/philosophy/

2. Transition Timeline

We plan to transition to a company with audit and supervisory committee structure after receiving approval for the necessary revisions to the articles of incorporation at the 22nd Ordinary General Meeting of Shareholders to be held in June 2025.

3. Other Matters

Going forward, details on matters including revisions to the articles of incorporation and on the executive structure will be announced once they are decided.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: https://www.alfresa.com/eng/